Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent.
Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions. This retrospective, observational study aimed to evaluate the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients treated with sirolimus-eluting stents (Cypher) and found that bivalirudin is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.
Washington Hospital Center, Washington, DC 20010, USA.
Seung-Woon
SW
Rha
Pramod K
PK
Kuchulakanti
Rajbabu
R
Pakala
Edouard
E
Cheneau
Jana A
JA
Fournadjiev
Ellen
E
Pinnow
Afework
A
Gebreeyesus
George
G
Aggrey
Zuyue
Z
Wang
Augusto D
AD
Pichard
Lowell F
LF
Satler
Kenneth M
KM
Kent
Joseph
J
Lindsay
Ron
R
Waksman
D000925:Anticoagulants / Q000627:therapeutic use*; D004337:Drug Carriers / Q000009:adverse effects*; D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006629:Hirudins / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents / Q000009:adverse effects*; D013927:Thrombosis / Q000209:etiology* / Q000517:prevention & control*
D000925:Anticoagulants; D004337:Drug Carriers; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D006493:Heparin; C074619:bivalirudin; D020123:Sirolimus